Ainos, Inc. reports developments tied to its transition toward AI-powered scent intelligence and industrial sensing. The company centers its commercial focus on AI Nose, an electronic olfaction platform that uses sensor arrays and proprietary artificial intelligence models, including its Smell Language Model, to convert volatile organic compound and scent signals into machine-readable Smell ID data.
Recurring news themes include AI Nose commercialization across semiconductor manufacturing, robotics, smart infrastructure, and healthcare-related environments; distribution and deployment relationships; industry classification updates; and financial results connected to the platform. Ainos also maintains a therapeutic-development program around VELDONA, a low-dose oral interferon program targeting rare, autoimmune, and infectious diseases.
Ainos, Inc. (NASDAQ:AIMD, AIMDW) has signed a Memorandum of Understanding with Taiwanese drug manufacturer Tah-An Chemical & Pharmaceutical Co., Ltd. to explore the feasibility of manufacturing an animal investigational new drug using its VELDONA® formulation. The collaboration aims to begin animal clinical trials in Q1 2023. Ainos will provide technical assistance while Tah-An will handle manufacturing, leveraging its experience since 1966. This partnership is viewed as a significant step in Ainos' commercialization strategy, capitalizing on Tah-An's manufacturing expertise to enhance its product pipeline.
Ainos, Inc. (NASDAQ: AIMD, AIMDW) shared a letter from CEO Chun-Hsien Tsai, reflecting on 2022's challenges and outlining growth strategies for 2023. The company successfully uplisted to Nasdaq in August 2022, enhancing its capital access. Notable projects include Ainos Flora, a non-invasive STI testing device, and VELDONA®, an interferon alpha treatment. Ainos aims to expand its product pipeline, with ongoing clinical studies and potential applications in veterinary medicine. Financially, Ainos reduced its debt ratio significantly from 75% to 6.8% and reported cash of $2.4 million. The company intends to avoid shareholder dilution while pursuing growth opportunities.
Ainos, Inc. (NASDAQ: AIMD) reported a remarkable 384.2% year-over-year revenue increase, totaling $1,757,774 in Q3 2022, driven primarily by robust sales of COVID-19 Antigen Self-Test Kits in Taiwan. Gross profit reached $581,742, with a gross margin of 33.1%. The company's debt ratio significantly improved to 6.8%, down from 75% at the end of 2021. Despite the growth in revenues, a net loss of $7,821,756 was reported. Ainos continues to focus on its innovative product pipeline, including upcoming Phase 2 trials for its VELDONA® oral interferon formulation.
Ainos, Inc. (NASDAQ: AIMD) has received positive FDA feedback on its Biologics License Application (BLA) for treating Sjögren's syndrome following two successful Phase 3 studies. The company is seeking out-licensing partnerships for five new drug candidates based on its low-dose oral interferon-alpha formulation, VELDONA®. These candidates have shown promising results in Phase 2 trials across various conditions, including aphthous stomatitis and influenza. Ainos aims to accelerate the commercialization of VELDONA® through these collaborations, having invested nearly $40 million in its development.
Ainos, Inc. (NASDAQ:AIMD, AIMDW) announced it is pursuing out-licensing opportunities for five new drug candidates of its low-dose oral interferon-alpha formulation, VELDONA. The candidates have successfully completed Phase 2 trials, with plans to accelerate them to Phase 3 and commercialization. The trials demonstrated VELDONA's effectiveness in treating various conditions, including Sjögren's syndrome and influenza. Ainos has invested nearly $40 million in the development of VELDONA and aims to enhance autoimmunity while minimizing side effects compared to high-dose injections.
Ainos, Inc. (NASDAQ:AIMD, AIMDW) announced positive results from its preclinical efficacy study of VELDONA®, a low-dose oral interferon formulation, against the Omicron variant of SARS-CoV-2. The study demonstrated significant stabilization in lung inflammation and recovery in hamsters treated with VELDONA®. The results led to an application for Phase 2 clinical trials in patients with mild COVID-19. The treatment showed a better recovery trend, with no observed mixed-cellular inflammation in the VELDONA® group, compared to 50% in the placebo group.
Ainos, Inc. (NASDAQ:AIMD, AIMDW) has submitted an Investigational New Drug (IND) application to the U.S. FDA for a Phase 2 trial of its low-dose oral interferon (IFN)-alpha formulation, VELDONA, aimed at treating mild COVID-19 symptoms. The trial will assess VELDONA's efficacy compared to standard care in a multicenter study in Taiwan. If successful, this could enhance treatments for COVID-19 and other viral infections.
Ainos, Inc. (NASDAQ:AIMD, AIMDW) has announced a Master Service Agreement with Swiss Pharmaceutical Co., Ltd. to test, manufacture, and package its VELDONA product candidates. This agreement aligns with Ainos' plans to submit an IND application for a Phase 2 study to the FDA by year-end. Additionally, Ainos is pursuing clinical trials for VELDONA against COVID-19 and has plans for further studies on thrombocytopenia and Sjögren's syndrome in 2023. This partnership aims to enhance Ainos' manufacturing capabilities and streamline its clinical trial preparations.
Ainos, a diversified medtech company, reported its second quarter financial results for 2022, showing a substantial revenue increase of 213.6% to US$636,627, driven by sales of COVID-19 Antigen Rapid Test Kits. Gross profit reached US$317,664, with a gross margin of 49.9%. However, total operating expenses surged 163.0% to US$2,261,960, impacting net loss, which increased to US$1,954,032. The company highlighted successful product developments, including an Emergency Use Authorization for its COVID-19 test kit in Taiwan, and progress on its VELDONA antiviral formulation.
Ainos, Inc. (NASDAQ:AIMD, AIMDW) has announced the closing of its public offering of 780,000 units at $4.25 per unit, yielding approximately $3.3 million in gross proceeds. Each unit includes one share of common stock and a warrant for one share. The stock underwent a reverse split at a 1-for-15 ratio, effective August 8, 2022. Additionally, the company granted underwriters a 45-day option to purchase an extra 117,000 shares and/or warrants. The offering was conducted under its SEC registration statement, effective as of August 8, 2022.